Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

about

Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma

P2860

Q58791292-567409BD-C952-4077-A2DE-A70550554DC0

P2860

Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

Item

http://www.wikidata.org/entity/Q36137083

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@ast

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@en

type

Item

label

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@ast

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@en

prefLabel

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@ast

Methylation of MGMT Is Associa ...... e III Duodenal Adenocarcinoma.

@en

P1476

Methylation of MGMT Is Associa ...... ge III Duodenal Adenocarcinoma

@en

P2093

Anup Sharmab

http://www.w3.org/2001/XMLSchema#string

Christopher L Wolfgang

http://www.w3.org/2001/XMLSchema#string

Fei Xie

http://www.w3.org/2001/XMLSchema#string

Kai Li

http://www.w3.org/2001/XMLSchema#string

Nita Ahuja

http://www.w3.org/2001/XMLSchema#string

Stephen B Baylin

http://www.w3.org/2001/XMLSchema#string

Weiwei Wan

http://www.w3.org/2001/XMLSchema#string

Yanliang Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for small intestine adenocarcinoma

MethyLight: a high-throughput assay to measure DNA methylation

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma

Low microsatellite instability is associated with poor prognosis in stage C colon cancer.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

P304

e0162929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0162929

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tao Fu

P577

2016-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27643594

http://www.w3.org/2001/XMLSchema#string

P932

5028050

http://www.w3.org/2001/XMLSchema#string

Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

about

P2860

P2860

Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932